- Home
- PM vs ABBV Comparison
PM vs ABBV Comparison
Compare PM & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PM | ABBV |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8B | 394.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PM | ABBV |
|---|---|---|
| Price | $153.18 | $222.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 18 |
| Target Price | $190.44 | ★ $242.28 |
| AVG Volume (30 Days) | ★ 5.6M | 5.4M |
| Earning Date | 10-21-2025 | 01-30-2026 |
| Dividend Yield | ★ 3.83% | 3.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.52 | 1.32 |
| Revenue | $39,992,000,000.00 | ★ $59,644,000,000.00 |
| Revenue This Year | $10.82 | $10.37 |
| Revenue Next Year | $7.66 | $9.41 |
| P/E Ratio | ★ $27.82 | $169.10 |
| Revenue Growth | ★ 7.45 | 7.40 |
| 52 Week Low | $116.12 | $164.39 |
| 52 Week High | $186.69 | $244.81 |
Technical Indicators
Market Signals| Indicator | PM | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 44.66 |
| Support Level | $146.65 | $220.23 |
| Resistance Level | $150.89 | $225.98 |
| Average True Range (ATR) | 3.28 | 4.54 |
| MACD | -0.14 | -0.76 |
| Stochastic Oscillator | 58.80 | 16.91 |
Price Performance
Historical ComparisonAbout PM Philip Morris International Inc
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.